The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Abstract
The objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia. In a randomized double-blind placebo-controlled study, 40 patients with chronic schizophrenia who were stabilized on risperidone for a minimum duration of eight weeks were recruited. The patients were randomly assigned to minocycline (titrated up to 200 mg/day) or placebo in addition to risperidone (maximum dose of 6 mg/day) for eight weeks. Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale, and Extrapyramidal Syndrome Rating Scale were used. Thirty-eight patients completed the study. Significant time × treatment interaction for negative [F(2.254,85.638)=59.046, P<0.001] general psychopathology [F(1.703,64.700)=6.819, P=0.001], and positive subscales [F(1.655,62.878)=5.193, P=0.012] as well as total PANSS scores [F(1.677,63.720)=28.420, P<0.001] were observed. The strongest predictors for change in negative symptoms were the treatment group (β=-0.94, t=-10.59, P<0.001) followed by the change in PANSS positive subscale (β=-0.185, t=-2.075, P=0.045). Side effect profiles of the two treatment regimens were not significantly different. Minocycline seems to be an efficacious and tolerable short-term add-on to risperidone for treatment of negative and general psychopathology symptoms of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Various clinical trials have been conducted using minocycline alone or as an adjunct to risperidone in patients with schizophrenia and have demonstrated overall improvement in negative symptoms and executive functioning (Miyaoka et al., 2008; Levkovitz et al., 2010; Khodaie-Ardakani et al., 2014).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Khodaie-Ardakani et al., 2014
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
The NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311
Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases
Amin, A. R., Attur, M. G., Thakker, G. D., Patel, P. D., Vyas, P., Patel, R. N., Patel, I. R., & Abramson, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14014 · Cited by 474
Persistent Negative Symptoms in Schizophrenia: An Overview
Buchanan, R. W. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl057 · Cited by 443
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
Chouinard, G., & Margolese, H. C. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.013 · Cited by 424
Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 414
Cited by
Sorted by citations
Items 101–104 of 104
Brief psychotic disorder caused by areca nut use: a case reportPreprint
Li, S., Li, Z., Li, Z., Chen, J., Wang, F., Ou, Y., & Huang, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3272471/v1
Hadi, F., Kashefinejad, S., Kamalzadeh, L., Hoobehfekr, S., & Shalbafan, M. (2021) · Figshare · doi:10.6084/m9.figshare.16935936
Zhang, Y., Zhao, J., Fan, Z., Wang, X., Shi, X., Wang, X., Wan, T., Du, F., Wu, K., & Jiang, W. (2026) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-026-10290-1
Yangyang, C., Chen, J., Xiao, X., Li, Y., Du, H., Min, W., & Zhang, X. (2026) · medRxiv · doi:10.64898/2026.07.29.26359223
Metadata
- Authors
- Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S.
- Affiliations
- Razi Hospital (IR)
- Roozbeh Hospital (IR)
- Kurdistan University of Medical Sciences (IR)
- Arak University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
- Corresponding author
- Akhondzadeh, Shahin
- ORCID
- Venue
- Psychiatry Research
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 215
- Issue
- 3
- Pages
- 540-546
- ISSN
- 0165-1781 (ISSN-L)
- OpenAlex
- W2070688969
- Cited by
- 104
- References
- 33
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 11 · 2020: 6 · 2019: 5 · 2018: 16 · 2017: 9 · 2016: 14 · 2015: 14 · 2014: 6
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatry Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tehran University of Medical Sciences (11921)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- minocycline, risperidone, schizophrenia, negative symptoms, adjunctive therapy, chronic schizophrenia, PANSS, extrapyramidal symptoms, depression, tolerability, neuroprotection
- MeSH terms
- Adult, Anti-Bacterial Agents, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Minocycline, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
